Announcements
- Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
- Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
- Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
- Idorsia holds its Annual General Meeting of Shareholders
- New data with daridorexant to be presented at SLEEP 2024
- Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
- Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
- Idorsia announces changes to Idorsia Executive Committee and Board of Directors
- Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
More ▼
Key statistics
On Friday, Idorsia Ltd (0RQE:LSE) closed at 2.13, 64.91% above the 52 week low of 1.29 set on Jan 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.08 |
---|---|
High | -- |
Low | -- |
Bid | 2.00 |
Offer | 2.21 |
Previous close | 2.07 |
Average volume | 49.87k |
---|---|
Shares outstanding | 189.09m |
Free float | 120.86m |
P/E (TTM) | -- |
Market cap | 404.65m CHF |
EPS (TTM) | -0.3534 CHF |
Data delayed at least 20 minutes, as of Jul 05 2024 16:06 BST.
More ▼